Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Cell > Fc gamma RI / CD64 > SCCHO-ATP062M

CHO/Human CD64 Stable Cell Line (Medium Expression) Development Service

Order Now

  • Description
    The CHO/Human CD64 Stable Cell Line was engineered to express full length human CD64 receptor (Gene ID: 2209), with different levels of CD64 expression (High, Medium, Low), which can be used to test agonist antibody whether in a CD64-dependent manner to strengthen the agonistic activity. When co-cultured with Human 4-1BB HEK293 Reporter Cell and anti-4-1BB agonist antibody, the anti-4-1BB antibody can be crosslinked, thereby strengthening 4-1BB pathway-activated luminescence.
  • Application

    • Useful for cell-based CD64 binding assay

    • Useful for CD64-mediated crosslinking

     Fc gamma RI / CD64 Assay Principles

  • Growth Properties
    Adherent
  • Selection Marker
    Hygromycin (20 μg/mL)
  • Culture Medium
    F-12K+ 10% FBS
  • Freeze Medium
    Serum-free cell cryopreservation medium
  • Quantity
    1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium
  • Storage
    Frozen in liquid nitrogen.
  • Mycoplasma Testing
    Negative
  • Sterility Testing
    Negative
  • Instructions for Use
    See data sheet for detailed culturing and assay protocol.
Receptor Assay
 Fc gamma RI / CD64 FACS

Expression analysis of human CD64 on CHO/Human CD64 Stable Cell Line by FACS.
Cell surface staining using PE-labeled anti-human CD64 antibody was performed on CHO/Human CD64 Stable Cell Line with different expression levels: CHO/Human CD64 Stable Cell Line (Low Expression); CHO/Human CD64 Stable Cell Line (Medium Expression); CHO/Human CD64 Stable Cell Line (High Expression).

Application
 Fc gamma RI / CD64 APPLICATION

Bioactivity analysis of anti-human 4-1BB antibody through CHO/Human CD64 Stable Cell Line (Medium Expression) crosslinking to test whether in a CD64-dependent manner to strengthen the agonistic activity.
The EC50 of anti-human 4-1BB antibody is approximately 0.49 μg/mL through CHO/Human CD64 Stable Cell Line (Medium Expression) crosslinking.

Please contact us if you are interested in related cell pool service.

  • Background
    Receptors that recognize the Fc portion of IgG are divided into three groups designated Fc gamma RI, RII, and RIII, also known respectively as CD64, CD32, and CD16. Fc gamma RI binds IgG with high affinity and functions during early immune responses. Fc gamma RII and RIII are low affinity receptors that recognize IgG as aggregates surrounding multivalent antigens during late immune responses. High affinity immunoglobulin gamma Fc receptor I is also known as FCGR1A, FCG1, FCGR1, CD64 and IGFR1, is a type of integral membrane glycoprotein that binds monomeric IgG-type antibodies with high affinity, which belongs to the immunoglobulin superfamily or FCGR1 family. FCGR1A / CD64 contains 3 Ig-like C2-type (immunoglobulin-like) domains. CD64 is constitutively found on only macrophages and monocytes, but treatment of polymorphonuclear leukocytes with cytokines like IFNγ and G-CSF can induce CD64 expression on these cells.
  • Permits & Restrictions
    This cell line is provided for research use only. It is not intended for any animal or human therapeutic use, any human or animal consumption, or any diagnostic use. You are not allowed to share, distribute, sell, modify, sublicense, or otherwise make this cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. AcroBiosystems does not warrant the suitability of this cell line for any particular use, and does not accept any liability in connection with the handling or use of this cell line.
  • Clinical and Translational Updates

Comments (0)


ETA of in-stock products: 2 business days

Price(USD) : $3500.00

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:0 Details
  • Number of Drugs in Clinical Trials:0 Details
  • Latest Research Phase:Discontinued

Datasheet & Documentation

Related Products

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message